Nuvelo, Inc., formed by the merger of Nuvelo Pharmaceuticals, Inc. and VARIAGENICS, Inc., is engaged in the discovery and development of biopharmaceutical and molecular diagnostic products. Nuvelo’s lead product candidate, alfimeprase, is partnered with Amgen and is currently in Phase I clinical trials. Additional programs include cancer diagnostics and drug discovery focused on cancer immunotherapeutics and secreted proteins. Nuvelo is leveraging its proprietary collection of novel and rarely expressed full-length human genes, coupled with an opportunistic in-licensing and partnering strategy, to support its efforts to build upon a pipeline of attractive therapeutic candidates.

(NASDAQ: NUVO)

People

Mary Pendergast (Board Member)

Michael Fleming (VP Commercial Operations)

James Gavin (Board Member)

Shelly Guyer (Chief Financial Officer, EVP Finance & Administration)

View more details about all 24 people at Nuvelo